 Claudia Amura
Concepts (259)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Buprenorphine | 2 | 2022 | 136 | 0.800 |
Why?
| | Cysts | 4 | 2009 | 93 | 0.730 |
Why?
| | Opioid-Related Disorders | 2 | 2022 | 417 | 0.620 |
Why?
| | Liver Diseases | 3 | 2009 | 282 | 0.580 |
Why?
| | Reperfusion Injury | 3 | 2013 | 276 | 0.530 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 3 | 2009 | 209 | 0.500 |
Why?
| | Kidney Tubules | 2 | 2012 | 128 | 0.490 |
Why?
| | Macrophage Activation | 3 | 1998 | 168 | 0.450 |
Why?
| | Cyst Fluid | 3 | 2009 | 27 | 0.420 |
Why?
| | Toll-Like Receptor 2 | 1 | 2012 | 127 | 0.410 |
Why?
| | Complement Factor B | 1 | 2012 | 102 | 0.400 |
Why?
| | TRPP Cation Channels | 3 | 2009 | 63 | 0.390 |
Why?
| | Cytokines | 7 | 2012 | 1900 | 0.370 |
Why?
| | Complement Activation | 2 | 2012 | 350 | 0.370 |
Why?
| | Toll-Like Receptor 4 | 1 | 2012 | 330 | 0.350 |
Why?
| | Liver | 2 | 2008 | 1816 | 0.340 |
Why?
| | Acute-Phase Proteins | 2 | 1998 | 67 | 0.320 |
Why?
| | Receptors, Interleukin-8B | 1 | 2008 | 23 | 0.320 |
Why?
| | Pyrroles | 2 | 2009 | 191 | 0.300 |
Why?
| | Lipopolysaccharides | 5 | 1999 | 870 | 0.300 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2007 | 103 | 0.290 |
Why?
| | Interleukin-8 | 1 | 2008 | 249 | 0.290 |
Why?
| | Epithelial Cells | 5 | 2012 | 963 | 0.280 |
Why?
| | Cell Proliferation | 3 | 2009 | 2275 | 0.280 |
Why?
| | Mitogen-Activated Protein Kinase 8 | 1 | 2005 | 16 | 0.280 |
Why?
| | Neurofilament Proteins | 1 | 2005 | 33 | 0.270 |
Why?
| | Indoles | 2 | 2009 | 316 | 0.270 |
Why?
| | Membrane Glycoproteins | 2 | 1998 | 446 | 0.270 |
Why?
| | Pluripotent Stem Cells | 1 | 2005 | 65 | 0.260 |
Why?
| | Telemedicine | 2 | 2023 | 664 | 0.260 |
Why?
| | Acute Kidney Injury | 1 | 2012 | 709 | 0.260 |
Why?
| | Piroxicam | 5 | 1995 | 5 | 0.240 |
Why?
| | Midwifery | 1 | 2023 | 41 | 0.220 |
Why?
| | Membrane Proteins | 3 | 2010 | 1055 | 0.220 |
Why?
| | Mice | 19 | 2013 | 15520 | 0.220 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 1998 | 1171 | 0.210 |
Why?
| | Nitrous Oxide | 1 | 2022 | 12 | 0.210 |
Why?
| | Labor Pain | 1 | 2022 | 6 | 0.210 |
Why?
| | Interleukin-1 | 3 | 1995 | 980 | 0.210 |
Why?
| | Analgesia, Obstetrical | 1 | 2022 | 16 | 0.210 |
Why?
| | Pseudomonas aeruginosa | 5 | 1995 | 305 | 0.200 |
Why?
| | Protein Kinase Inhibitors | 1 | 2007 | 811 | 0.200 |
Why?
| | Chemotaxis, Leukocyte | 4 | 1995 | 133 | 0.200 |
Why?
| | Cells, Cultured | 6 | 2012 | 4077 | 0.200 |
Why?
| | Academic Performance | 1 | 2021 | 15 | 0.190 |
Why?
| | Faculty, Nursing | 1 | 2021 | 21 | 0.190 |
Why?
| | Mice, Knockout | 5 | 2012 | 2680 | 0.190 |
Why?
| | Macrophages, Peritoneal | 2 | 1998 | 96 | 0.190 |
Why?
| | Education, Nursing, Graduate | 1 | 2021 | 23 | 0.190 |
Why?
| | Crime Victims | 1 | 2022 | 80 | 0.190 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2005 | 814 | 0.190 |
Why?
| | Intimate Partner Violence | 1 | 2022 | 70 | 0.190 |
Why?
| | Pilot Projects | 2 | 2022 | 1419 | 0.180 |
Why?
| | Students, Nursing | 1 | 2021 | 55 | 0.180 |
Why?
| | Chemotactic Factors | 3 | 1993 | 51 | 0.170 |
Why?
| | Kidney | 3 | 2013 | 1353 | 0.170 |
Why?
| | Mice, Inbred C57BL | 6 | 2012 | 4908 | 0.170 |
Why?
| | Agranulocytosis | 2 | 1995 | 31 | 0.160 |
Why?
| | Perception | 1 | 2021 | 314 | 0.160 |
Why?
| | Lung Diseases | 2 | 1995 | 718 | 0.160 |
Why?
| | Asthma | 2 | 2023 | 2158 | 0.160 |
Why?
| | Altitude | 1 | 2022 | 422 | 0.160 |
Why?
| | Animals | 20 | 2013 | 33381 | 0.150 |
Why?
| | Colorado | 3 | 2022 | 4196 | 0.150 |
Why?
| | Neurons | 1 | 2005 | 1345 | 0.150 |
Why?
| | Carrier Proteins | 2 | 1998 | 726 | 0.150 |
Why?
| | Pseudomonas Infections | 2 | 1995 | 193 | 0.140 |
Why?
| | Sepsis | 2 | 1999 | 531 | 0.140 |
Why?
| | Anti-Asthmatic Agents | 1 | 2019 | 343 | 0.140 |
Why?
| | Neutrophils | 4 | 1995 | 1233 | 0.130 |
Why?
| | Glucocorticoids | 1 | 2019 | 545 | 0.130 |
Why?
| | Signal Transduction | 4 | 2012 | 4709 | 0.130 |
Why?
| | Mice, Inbred C3H | 4 | 1998 | 250 | 0.130 |
Why?
| | Length of Stay | 1 | 2019 | 1032 | 0.130 |
Why?
| | Analgesics, Opioid | 1 | 2022 | 794 | 0.120 |
Why?
| | Promoter Regions, Genetic | 3 | 2008 | 1158 | 0.120 |
Why?
| | Endothelial Cells | 2 | 2009 | 732 | 0.110 |
Why?
| | Emergency Service, Hospital | 2 | 2023 | 1864 | 0.110 |
Why?
| | Copper | 1 | 1993 | 102 | 0.110 |
Why?
| | Immunity, Humoral | 1 | 2013 | 117 | 0.110 |
Why?
| | Health Behavior | 1 | 2018 | 720 | 0.100 |
Why?
| | Transplantation, Homologous | 1 | 2013 | 415 | 0.100 |
Why?
| | Cell Line | 2 | 2008 | 2707 | 0.100 |
Why?
| | Superoxide Dismutase | 1 | 1993 | 339 | 0.100 |
Why?
| | Pediatric Obesity | 1 | 2018 | 524 | 0.100 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 2 | 2009 | 86 | 0.100 |
Why?
| | Complement Inactivator Proteins | 1 | 2010 | 39 | 0.090 |
Why?
| | B-Lymphocyte Subsets | 1 | 2010 | 66 | 0.090 |
Why?
| | Receptors, Complement | 1 | 2010 | 115 | 0.090 |
Why?
| | Complement Factor H | 1 | 2010 | 61 | 0.090 |
Why?
| | Humans | 16 | 2023 | 118972 | 0.090 |
Why?
| | Graft Rejection | 1 | 2013 | 555 | 0.090 |
Why?
| | Kidney Diseases | 1 | 2013 | 439 | 0.080 |
Why?
| | Chemokine CXCL5 | 1 | 2008 | 11 | 0.080 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2007 | 1945 | 0.080 |
Why?
| | Chemokine CXCL1 | 1 | 2008 | 69 | 0.080 |
Why?
| | Cell Shape | 1 | 2008 | 57 | 0.080 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2009 | 527 | 0.080 |
Why?
| | Cell Differentiation | 2 | 2005 | 1753 | 0.080 |
Why?
| | Transcription, Genetic | 2 | 2008 | 1323 | 0.080 |
Why?
| | Antimicrobial Cationic Peptides | 2 | 1998 | 78 | 0.080 |
Why?
| | Injections, Intraperitoneal | 3 | 1998 | 108 | 0.080 |
Why?
| | Female | 14 | 2023 | 61564 | 0.080 |
Why?
| | Exercise | 1 | 2018 | 1657 | 0.080 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2007 | 67 | 0.070 |
Why?
| | Epithelial Sodium Channels | 1 | 2006 | 12 | 0.070 |
Why?
| | Cell Polarity | 1 | 2008 | 133 | 0.070 |
Why?
| | Cell Hypoxia | 1 | 2008 | 220 | 0.070 |
Why?
| | Kidney Transplantation | 1 | 2013 | 585 | 0.070 |
Why?
| | Bile Ducts | 1 | 2006 | 73 | 0.070 |
Why?
| | Mice, Neurologic Mutants | 1 | 2005 | 19 | 0.070 |
Why?
| | Blood Proteins | 2 | 1998 | 248 | 0.070 |
Why?
| | Stress, Mechanical | 1 | 2008 | 443 | 0.070 |
Why?
| | Wnt4 Protein | 1 | 2005 | 18 | 0.070 |
Why?
| | Disease Models, Animal | 4 | 2009 | 3730 | 0.070 |
Why?
| | Luciferases | 1 | 2005 | 143 | 0.070 |
Why?
| | Transfection | 1 | 2008 | 888 | 0.070 |
Why?
| | Genes, Reporter | 1 | 2005 | 270 | 0.060 |
Why?
| | Pandemics | 2 | 2023 | 1355 | 0.060 |
Why?
| | Embryo, Mammalian | 1 | 2005 | 220 | 0.060 |
Why?
| | Nerve Growth Factor | 1 | 2004 | 29 | 0.060 |
Why?
| | Wnt Proteins | 1 | 2005 | 140 | 0.060 |
Why?
| | Cadherins | 1 | 2005 | 186 | 0.060 |
Why?
| | Peroxidase | 2 | 1995 | 170 | 0.060 |
Why?
| | Adult | 2 | 2022 | 31512 | 0.060 |
Why?
| | Down-Regulation | 1 | 2005 | 627 | 0.060 |
Why?
| | Certification | 1 | 2023 | 99 | 0.050 |
Why?
| | Time Factors | 2 | 2007 | 6412 | 0.050 |
Why?
| | Liver Neoplasms | 1 | 2006 | 527 | 0.050 |
Why?
| | Nurse's Role | 1 | 2023 | 102 | 0.050 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2004 | 770 | 0.050 |
Why?
| | Tennessee | 1 | 2022 | 44 | 0.050 |
Why?
| | Proto-Oncogene Proteins | 1 | 2005 | 618 | 0.050 |
Why?
| | RNA, Messenger | 3 | 2005 | 2657 | 0.050 |
Why?
| | North Carolina | 1 | 2022 | 109 | 0.050 |
Why?
| | Workflow | 1 | 2023 | 148 | 0.050 |
Why?
| | Bronchodilator Agents | 1 | 2023 | 253 | 0.050 |
Why?
| | Cell Line, Tumor | 1 | 2008 | 2851 | 0.050 |
Why?
| | Pregnancy | 2 | 2023 | 5690 | 0.050 |
Why?
| | House Calls | 1 | 2022 | 133 | 0.050 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2008 | 2062 | 0.050 |
Why?
| | Violence | 1 | 2022 | 218 | 0.040 |
Why?
| | Opiate Substitution Treatment | 1 | 2020 | 96 | 0.040 |
Why?
| | Fatty Acids, Monounsaturated | 1 | 1999 | 46 | 0.040 |
Why?
| | Thioglycolates | 1 | 1998 | 3 | 0.040 |
Why?
| | Galactosamine | 1 | 1998 | 4 | 0.040 |
Why?
| | Policy | 1 | 2020 | 133 | 0.040 |
Why?
| | Immune Sera | 1 | 1998 | 82 | 0.040 |
Why?
| | Qualitative Research | 1 | 2023 | 953 | 0.040 |
Why?
| | Time-to-Treatment | 1 | 2019 | 149 | 0.040 |
Why?
| | Blood Bactericidal Activity | 1 | 1997 | 37 | 0.040 |
Why?
| | Interleukin-12 | 1 | 1998 | 110 | 0.040 |
Why?
| | Recombinant Proteins | 3 | 1998 | 1308 | 0.040 |
Why?
| | Leadership | 1 | 2021 | 311 | 0.040 |
Why?
| | Drug Administration Schedule | 1 | 2019 | 736 | 0.040 |
Why?
| | Biological Transport | 1 | 1998 | 382 | 0.040 |
Why?
| | Urban Population | 1 | 2019 | 409 | 0.040 |
Why?
| | Child | 3 | 2023 | 19129 | 0.040 |
Why?
| | Enzyme Activation | 1 | 1998 | 828 | 0.040 |
Why?
| | Interleukin-10 | 1 | 1998 | 306 | 0.030 |
Why?
| | Immunization | 1 | 1998 | 412 | 0.030 |
Why?
| | Mothers | 1 | 2022 | 682 | 0.030 |
Why?
| | Child Behavior | 1 | 2018 | 212 | 0.030 |
Why?
| | Hospitals, Pediatric | 1 | 2019 | 505 | 0.030 |
Why?
| | Parent-Child Relations | 1 | 2018 | 232 | 0.030 |
Why?
| | Acute-Phase Reaction | 1 | 1995 | 39 | 0.030 |
Why?
| | ADP Ribose Transferases | 1 | 1995 | 10 | 0.030 |
Why?
| | Exotoxins | 1 | 1995 | 15 | 0.030 |
Why?
| | Quality Improvement | 1 | 2023 | 963 | 0.030 |
Why?
| | Gene Expression Regulation | 1 | 2004 | 2445 | 0.030 |
Why?
| | Protein-Tyrosine Kinases | 1 | 1998 | 407 | 0.030 |
Why?
| | Mutation | 1 | 2005 | 3457 | 0.030 |
Why?
| | Kinetics | 1 | 1998 | 1624 | 0.030 |
Why?
| | Monocytes | 1 | 1997 | 513 | 0.030 |
Why?
| | Male | 7 | 2019 | 57801 | 0.030 |
Why?
| | Bacterial Toxins | 1 | 1995 | 106 | 0.030 |
Why?
| | Superoxides | 1 | 1995 | 221 | 0.030 |
Why?
| | In Vitro Techniques | 2 | 1993 | 1094 | 0.030 |
Why?
| | Registries | 1 | 2022 | 1810 | 0.030 |
Why?
| | Health Services Accessibility | 1 | 2020 | 781 | 0.030 |
Why?
| | Retrospective Studies | 2 | 2022 | 12978 | 0.030 |
Why?
| | Virulence Factors | 1 | 1995 | 140 | 0.030 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 1993 | 72 | 0.030 |
Why?
| | Copper Sulfate | 1 | 1993 | 6 | 0.030 |
Why?
| | Cytochrome c Group | 1 | 1993 | 37 | 0.030 |
Why?
| | Edetic Acid | 1 | 1993 | 47 | 0.030 |
Why?
| | Lung | 3 | 1995 | 3664 | 0.030 |
Why?
| | Antibody Formation | 2 | 2010 | 276 | 0.030 |
Why?
| | Electronic Health Records | 1 | 2019 | 829 | 0.030 |
Why?
| | Mammary Neoplasms, Experimental | 1 | 1992 | 63 | 0.030 |
Why?
| | Edema | 1 | 1993 | 124 | 0.030 |
Why?
| | Algorithms | 1 | 2019 | 1541 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2674 | 0.030 |
Why?
| | Administration, Inhalation | 1 | 1993 | 656 | 0.020 |
Why?
| | Macrophages | 1 | 1998 | 1324 | 0.020 |
Why?
| | Practice Patterns, Physicians' | 1 | 2019 | 1200 | 0.020 |
Why?
| | In Situ Nick-End Labeling | 1 | 2010 | 124 | 0.020 |
Why?
| | Transcription Factors | 1 | 1998 | 1570 | 0.020 |
Why?
| | Receptors, Complement 3b | 1 | 2010 | 82 | 0.020 |
Why?
| | Adolescent | 2 | 2019 | 18480 | 0.020 |
Why?
| | Body Mass Index | 1 | 2018 | 2092 | 0.020 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 1992 | 304 | 0.020 |
Why?
| | Oxidation-Reduction | 1 | 1993 | 940 | 0.020 |
Why?
| | NIMA-Interacting Peptidylprolyl Isomerase | 1 | 2009 | 19 | 0.020 |
Why?
| | Peptidylprolyl Isomerase | 1 | 2009 | 10 | 0.020 |
Why?
| | Complement Pathway, Alternative | 1 | 2010 | 117 | 0.020 |
Why?
| | Immunoglobulin M | 1 | 2010 | 253 | 0.020 |
Why?
| | Pneumonia | 1 | 1994 | 592 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2021 | 4708 | 0.020 |
Why?
| | Polymerase Chain Reaction | 2 | 2004 | 1012 | 0.020 |
Why?
| | Microscopy, Fluorescence | 1 | 2010 | 412 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 827 | 0.020 |
Why?
| | Blotting, Western | 1 | 2010 | 1194 | 0.020 |
Why?
| | Neovascularization, Pathologic | 1 | 2009 | 287 | 0.020 |
Why?
| | Receptors, Purinergic P2X4 | 1 | 2006 | 4 | 0.020 |
Why?
| | Receptors, Purinergic P2 | 1 | 2006 | 20 | 0.020 |
Why?
| | Amiloride | 1 | 2006 | 24 | 0.020 |
Why?
| | Ion Transport | 1 | 2006 | 60 | 0.020 |
Why?
| | Chlorine | 1 | 2006 | 55 | 0.020 |
Why?
| | Bacterial Proteins | 1 | 1992 | 759 | 0.020 |
Why?
| | Young Adult | 1 | 2022 | 10793 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2010 | 1691 | 0.020 |
Why?
| | Mice, Inbred Strains | 1 | 2006 | 405 | 0.020 |
Why?
| | Adenocarcinoma | 1 | 1992 | 812 | 0.020 |
Why?
| | Cyclic AMP | 1 | 2006 | 242 | 0.020 |
Why?
| | Sodium | 1 | 2006 | 200 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 2009 | 827 | 0.020 |
Why?
| | Synapsins | 1 | 2004 | 13 | 0.020 |
Why?
| | PC12 Cells | 1 | 2004 | 40 | 0.020 |
Why?
| | Phosphorylation | 1 | 2009 | 1633 | 0.020 |
Why?
| | Protein Binding | 1 | 2010 | 1975 | 0.020 |
Why?
| | Adenosine Triphosphate | 1 | 2006 | 439 | 0.020 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2004 | 155 | 0.020 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2004 | 160 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-fos | 1 | 2004 | 193 | 0.010 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2004 | 237 | 0.010 |
Why?
| | N-Formylmethionine Leucyl-Phenylalanine | 2 | 1993 | 67 | 0.010 |
Why?
| | Transcriptional Activation | 1 | 2004 | 348 | 0.010 |
Why?
| | Endothelium, Vascular | 1 | 2009 | 907 | 0.010 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2004 | 287 | 0.010 |
Why?
| | Lung Neoplasms | 1 | 1992 | 2220 | 0.010 |
Why?
| | Spermine | 1 | 1999 | 28 | 0.010 |
Why?
| | Gram-Negative Bacteria | 1 | 1999 | 70 | 0.010 |
Why?
| | Neutralization Tests | 1 | 1998 | 66 | 0.010 |
Why?
| | Glycine | 1 | 1999 | 162 | 0.010 |
Why?
| | Gene Expression Profiling | 1 | 2004 | 1597 | 0.010 |
Why?
| | DNA Primers | 1 | 1998 | 533 | 0.010 |
Why?
| | Rats | 1 | 2004 | 5392 | 0.010 |
Why?
| | Interferon-gamma | 1 | 1998 | 736 | 0.010 |
Why?
| | Base Sequence | 1 | 1998 | 2159 | 0.010 |
Why?
| | Culture Media | 1 | 1993 | 163 | 0.010 |
Why?
| | Nitric Oxide | 1 | 1998 | 892 | 0.010 |
Why?
| | Neoplasm Transplantation | 1 | 1992 | 245 | 0.010 |
Why?
| | Aerosols | 1 | 1993 | 221 | 0.010 |
Why?
| | Antibodies, Monoclonal | 1 | 1998 | 1284 | 0.010 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 1993 | 613 | 0.010 |
Why?
| | Phenotype | 1 | 1998 | 3003 | 0.010 |
Why?
| | Mice, Inbred BALB C | 1 | 1992 | 1206 | 0.010 |
Why?
| | Combined Modality Therapy | 1 | 1992 | 1166 | 0.010 |
Why?
|
|
Amura's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|